Rineterkib hydrochloride (C09-1167-284)

Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer , KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.In VivoERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Calu-6 NSCLC xenograft tumor models in mice . Dosage: 50, 75 mg/kg. Administration: Orally either daily (qd) or every other day (q2d) for 27 days. Result: Significantly reduced the tumor volume.Form:Solid. Specifications and Purity: 99%. Molecular Formula: C26H28BrClF3N5O2. PubChem CID: 154572843. Isomeric SMILES: CNC[C@H](C1=CC(=CC(=C1)Br)F)NC(=O)C2=C(C=C(C=C2)C3=NC(=CN=C3N)[C@H]4CC[C@@H]([C@H](C4)F)O)F.Cl.